AbbVie will buy venture-backed startup Stemcentrx for $5.8 billion, beefing up the biopharma giant’s portfolio of cancer drugs.
The sale could be worth $4 billion more if San Francisco-based Stemcentrx meets development milestones. Plus, as Business Insider reported, the startup has $400 million in the bank, potentially making the entire deal worth $10.2 billion.